Managed Care Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aphios Corporation
Deal signed with Japanese firms to develop anticancer therapeutic
August 16th, 2005
Aphios Corporation announced that it has entered a research and development collaboration with two Japanese companies, Bio Research Corporation of Yokohama, Yokohama, Japan, and Tokyo Supply, Ltd., Minato, Japan, to develop an orally-bioavailble anticancer therapeutic. The collaborators plan to develop a water-soluble paclitaxel prodrug. The molecule is a combination of a paclitaxel molecule, the potent anticancer drug, and a sugar molecule that enhances solubility. This molecular combination is not bioactive prior to treatment and is significantly more water-soluble than paclitaxel. The water-soluble nature of this novel therapeutic allows for oral...
Source: Managed Care Business Week (2005-08-16)
|
